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Toll-like receptors (TLRs) are expressed by immune cells, intestinal epithelium, and tumor
cells. In the homeostatic setting, they help to regulate control over invading pathogens
and maintain the epithelial lining of the large and small intestines. Aberrant expression of
certainTLRs by tumor cells can induce growth inhibition while others contribute to tumori-
genesis and progression. Activation of these TLRs can induce inflammation, tumor cell
proliferation, immune evasion, local invasion, and distant metastasis.TheseTLR-influenced
behaviors have similarities with properties observed in leukocytes, suggesting that tumors
may be hijacking immune programs to become more aggressive. The concept of epithe-
lial to leucocytic-transition (ELT) is proposed, akin to epithelial to mesenchymal transition,
in which tumors develop the ability to activate leucocytic traits otherwise inaccessible
to epithelial cells. Understanding the mechanisms of ELT could lead to novel therapeutic
strategies for inhibiting tumor metastasis.
Keywords: colorectal cancer, toll-like receptors, epithelial to leucocytic transition, ELT, metastasis, immune evasion,
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INTRODUCTION
Toll-like receptors (TLRs) are a diverse family of pattern recog-
nition receptors expressed by immune cells from both the innate
and adaptive arms of the immune system (1–4). Hence, TLRs
stimulate both innate and adaptive immune responses to invad-
ing pathogen-associated molecular patterns (PAMPs) as well as
danger-associated molecular patterns (DAMPs) from damaged
epithelial cells. Ligand specificity, downstream signaling, and sub-
sequent immune stimulation vary greatly among the TLR subtypes
(5, 6). The complex expression patterns of TLRs differ among cell
types, physiological location, and are controlled by the microen-
vironment (7–9). In the healthy gastrointestinal (GI) tract, TLRs
are expressed by intestinal epithelial cells (IEC) and play a role in
immune modulation and tissue homeostasis by stimulating the
immune response to bacterial pathogens, attenuating the immune
response against favorable microbes, sensing breakdown of the
protective intestinal barriers, and triggering proliferative signaling
(6, 10, 11). The lumen of the gut is subjected to continual inter-
actions with the microbiome and would be in a constant state of
inflammation were it not for the controlled expression and normal
function of these TLRs (2, 6).
Inflammation has been implicated as an underlying factor
in tumorigenesis and cancer progression, leading transformed
cells to develop the “hallmarks of cancer” (12, 13). Some of the
same TLRs (TLR 2–4) that normally regulate inflammation in
the gut are also found to be aberrantly expressed in colorec-
tal cancers (CRCs) (14, 15). Overexpression of TLR4 in CRC is
associated with poor survival (16). Deletion of TLR4, its signal-
ing partner Myd88, or absence of its ligand LPS in the colon
can lead to increased or reduced inflammation, depending on
the cancer subtype, which can then lead to either increased or
decreased tumorigenesis and tumor progression (17, 18). It is
notable that the role of TLRs in CRC reflects a “natural his-
tory” of selection events that lead from normal TLR function
in unaffected colon tissue and throughout all stages of CRC
progression. More specifically, the normal role of TLR immune
modulation in the gut involves the controlled release of cytokines
and danger signals that stimulate the immune response to bac-
terial pathogens and attenuate the immune response against
favorable microbes (6, 10). Microbial imbalance and/or dysreg-
ulation of these responses leads to chronic inflammation of the
bowel (15). Chronic inflammation is correlated with initiation
of cancer development and in the progression of cancer into
more aggressive forms of malignancies (2). Aberrant TLR sig-
naling and the resulting cytokine imbalance leads to increased
epithelial proliferation and decreased cell death (19). Addition-
ally, an active immune environment creates selection pressures for
initiating cancer cells resulting in the evolution of an immune-
evasive tumor phenotype (14). Furthermore, TLR dysregulation
is implicated in cancer invasion and metastasis (2, 19–21). Under-
standing the role of TLRs in the natural evolution of metastatic
disease is crucial for developing new therapies and optimizing
current treatments.
ROLE OF TLRs IN INFLAMMATION-MEDIATED
TUMORIGENESIS
The intestines house approximately 70% of the body’s immune
cells under normal conditions (10). Signaling between these
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immune cells, commensal bacteria, and IECs is critical for normal
digestion and protection against invading pathogens (6). TLRs
are key modulators of the immune system of the GI tract. In
order to maintain homeostasis and suppress immune responses
to commensal bacteria (11), TLR expression and signaling are
tightly controlled in this environment (6, 20). However, these
controls are disrupted in diseases such as Crohn’s disease and
ulcerative colitis, resulting in chronic inflammation (11, 15).
Inflammation is linked to cancer through two pathways: extrinsic
inflammation induced by non-transformed cells (e.g., invading
pathogens or autoimmune disease), and intrinsic inflammation
induced by transformed cells (22). In CRC, TLRs are involved
in both. Autoimmune diseases cause chronic, smoldering lev-
els of inflammation that predispose individuals into develop-
ing CRC (22). Once initiated, tumors can intrinsically activate
inflammation through TLR binding by cancer-related DAMPs.
Intrinsically and extrinsically induced TLR activation results in
tumor-promoting inflammation through NF-κB signaling, lead-
ing to expression of the inflammatory cytokines IL-1β, TNFα, and
IL-6 (17). This aberrant expression by tumor cells in early car-
cinogenesis can recruit tumor-promoting immune cells, leading
to inflammation and protection from cytotoxic immune cells.
Additional data from Kim et al. links mutations in p53 and
PTEN to SOCS-mediated activation of IL-6 signaling, leading
to intrinsic inflammation (23). Since p53 mutation is a very
common event in the natural history of CRC, this is likely a
major mechanism of tumor-induced inflammation. Addition-
ally, inflammation can drive genetic and epigenetic changes in
cells as well as possible alterations in lineage differentiation pro-
grams leading to increased plasticity. This process is also thought
to involve NF-κB signaling; however, further studies are needed
(22, 24).
ROLE OF TLRs IN INFLAMMATION-MEDIATED
PROLIFERATION AND SURVIVAL
Inflammatory pathways are tightly linked to aberrant prolifer-
ation and resistance to cell death, which are key cancer hall-
marks that can be mediated through TLR activation (14). IECs
are the barrier layer that protects the interstitial layers from
the changing exterior environment of the GI tract. Infiltrat-
ing bacteria and the resulting immune response can cause tis-
sue damage. To prepare for this, IECs utilize TLR4 signaling
as an early warning system to initiate proliferation, maintain
tissue integrity, and protect the interstitial compartments (6).
Tumors can co-opt this system, allowing cells to proliferate
unchecked (25).
Tumor growth is further fueled through an overabundance
of growth factors (e.g., TGF-β, IL-8, CXCR4, and VEGF)
(15), a decline in immune surveillance, and the evolution of
mobile and invasive phenotypes. TLR expression on tumor
cells stimulates the release of cytokines that recruit favorable
immune cells further driving proliferation. Additionally, the
release of cytokines and chemokines due to TLR signaling gen-
erates an autocrine loop that further stimulates tumor cell
growth. The cumulative result is tumor control over its own
environment.
ROLE OF TLRs IN IMMUNE EVASION
An active immune environment selects for the natural evolution
of cancer cells with decreased immunogenic phenotypes. TLR
expression in tumors can confer the advantages of both immune
evasion and immunosuppression (26). Often pro-inflammatory
signals reduce elements of the adaptive immune response. TLR sig-
naling causes a shift in this response from anti-tumor to pro-tumor
by affecting the balance toward inflammation and suppression of
anti-tumor immunity. Direct TLR activation results in produc-
tion of immunosuppressive cytokines IL-10 and TGF-β (14, 27),
as well as increased expression of immune modulating surface
markers PD-L1 and HLA-G (19, 20, 28). These secreted and surface
proteins have a tolerizing effect on immune cells. TLR-activated
IECs induce the transformation of dendritic cells (DC) into an
antigen-specific CD103+ phenotype. These DC promote contact-
dependent antigen-specific regulatory T cells (Tregs) that express
gut-homing integrins, which further attenuates the anti-tumor
immune response (10). Each of these mechanisms are used in the
healthy gut to avoid food hypersensitivity or auto-immune dis-
eases. However, dysregulation through abnormal TLR expression
can lead to malignant progression.
ROLE OF TLRs IN INVASION AND METASTASIS
The most dangerous effect of tumoral TLR signaling is the acqui-
sition of invasive and metastatic tumor phenotypes (29). Ninety
percent of patients who succumb to their disease have metasta-
tic lesions (30). TLR expression in tumors is linked to increased
grade and distant metastasis (2, 18, 21, 31). The ability of a
tumor cell to detach from its epithelial neighbors, break through
the basement membrane, and invade nearby tissues is, in part,
the result of a long history of aberrant TLR signaling. In CRC,
TLR-mediated alterations of the immune system components in
the tumor microenvironment can change intracellular signaling
(NF-κB), integrin expression (B1 integrin), and motility (29, 32).
Activation of TLR4 by LPS in vitro and in vivo induces epithe-
lial to mesenchymal transition (EMT) and invasive phenotypes in
certain cell lines (29, 33).
Immune cells are educated by tumor-secreted factors and then
actively migrate through the lymphatic vessels and secondary lym-
phoid organs. These tightly gated organs allow entry and passage
to soluble antigens and select immune cell phenotypes, and yet
lymph nodes are often the first site of metastasis (34). While it
was once thought that tumors cells passively filter into draining
lymph nodes, it has recently been shown that tumor cells require
chemokine-mediated (CCR7 and CCR8) active transport through
the subcapsular sinus epithelium (35, 36). Furthermore, it has been
shown that tumor-mediated lymphatic remodeling of peritumoral
lymph vessels and draining lymph nodes facilitates metastasis (37–
40). TLRs may play a role in this metastatic process, since TLR
activation leads to increased expression of CCR7 and CCR8 (41),
which are key molecules expressed by leukocytes to access lym-
phatics (35, 42). This suggests that the tumor cells can harness
existing leucocytic mechanisms to begin the metastatic cascade
through the lymph nodes.
Lymphocytes typically traffic throughout the body to sites
of inflammation, using chemokines, selectins, and integrins as
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homing signals (43). Many metastatic tumors have been shown
to use the expression of these same molecules to colonize dis-
tal sites (44, 45). As an example, CXCR4 is a well-characterized
bone marrow homing receptor expressed by T cells (46); research
has found that both prostate cancers (47) and breast cancers (48)
that metastasize to the bone commonly express CXCR4. CRC
typically metastasizes to the liver or lung. Aberrant expression
of CXCR3, CXCR4/CXCR7, and CCR6 are commonly found in
liver and lung metastasis of colon cancer (49–55). Ligands for
these receptors (CXCL19, SDF-1, and CCL20, respectively) are
highly expressed in the liver and lungs of metastatic CRC patients
(53, 56–58). Local inflammation in these organs induces ligand
expression and preferential organ metastasis is determined by their
expression (59, 60).
Alteration in integrin signaling is another metastatic mecha-
nism induced by TLR signaling (26). Integrin signaling is used
in healthy systems to aid immune cell trafficking (61). Aberrant
expression of these integrins via TLR signaling allows circulating
tumor cells to respond to the same trafficking mechanisms that an
immune cell uses to migrate to distal sites (2, 32, 62, 63). Similar
examples have been shown with integrins in colon cancer (64),
breast cancer (65), and melanoma (66). These expressed surface
markers are a natural part of the lymphocytic trafficking system,
and their expression on tumor cells could be evidence that tumor
cells use leucocytic trafficking mechanisms to metastasize.
EPITHELIAL TO LEUCOCYTIC TRANSITION
The co-opting of immune cell signaling and migration mecha-
nisms by tumor cells is well documented, with many citing the
plasticity of tumor cells and inappropriate gene expression as the
underlying cause of treatment resistance and metastatic growth
(13, 67–70). Pressures from cytotoxic immune cells, abundant
inflammation, cytotoxic drugs, and targeted therapies push tumor
cells into plastic states where they may begin to access programed
mechanisms outside of their usual function (68). The survivors
of these selection pressures are adaptive and dynamic cells, many
of which express patterns of proteins found in other normal cell
types (70, 71). These protein expression patterns have been used
to define and detect EMT, for example. An increasing number of
publications suggest that although EMT is important in locally
invasive disease, it is not enough to allow tumor cells access to
lymph nodes, lymphatic and vascular systems, as well as entrance
and settlement into distant tissues (35, 69, 72, 73). Others hypoth-
esize a myeloid lineage expression pattern gained from horizontal
gene transfer and Lamarckian inheritance, tumor cell myeloid cell
fusion, or a possible myeloid cell origin (69, 74–76). Here, we build
on these observations and propose a new concept, the transition
from epithelial phenotype to leucocytic phenotype.
Immune cells of myeloid and lymphoid origins house a diverse
set of mechanisms that make them perfect trafficking cells. They
can shift their metabolism easily, survive in low oxygenated areas,
roll along the endothelium in the presence of high shear forces,
read integrin codes, and facilitate tissue specific extravasation (77–
79). As described above, the aberrant expression of TLRs by CRC
cells results in the acquisition of a number of tumor-promoting
mechanisms. At the same time, these mechanisms are key prop-
erties of the immune system, as is TLR expression. In a broad
sense, immunosuppression, migration through tissue, intra- and
extravasation through lymph and blood vessels, rapid prolifera-
tion, altered metabolism, and homing to specific tissues are key
hallmarks of both cancer and the immune system.
Pathogenic EMT has its roots in normal embryogenesis. In
cancer, this transition results in epithelial cells with a range of
mesenchymal protein expression. These alterations increase motil-
ity and invasive capability of tumor cells, but do not necessarily
explain immunoevasion, lymphatic access, and metastatic spread
(35, 69, 72). We therefore propose the parallel concept of epithe-
lial to leucocytic transition (ELT) as a framework, akin to EMT,
with which to understand the metastatic properties of cancer cells.
Figure 1 illustrates the primary properties gained by tumor cells
that undergo ELT. We consider ELT to be a partial transition in
which epithelial cells retain their epithelial origin while at the same
time acquiring a set of leucocytic traits. Tumor cells co-opt many
mechanisms of the immune system for their own transport and
these mechanisms are activated by proteins typically reserved for
FIGURE 1 | Epithelial to leucocytic transition (ELT) is the acquisition of
immune properties by tumor cells. Epithelial tumor cells (purple box) can
make transition to a mesenchymal phenotype (orange box), which
enhances local motility and remodeling of the extracellular matrix (ECM).
Tumor cells undergoing ELT (green box) can gain the ability to (1) evade the
immune system at the primary tumor site, (2) access the lymphatic system,
(3) circulate through the vasculature, home to favorable sites of metastasis,
and extravasate into a metastatic niche, and (4) avoid destruction by the
immune system at the site of metastasis.
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the immune response. A leucocytic tumor cell expresses proteins
that allow for regulation and co-opting of the immune system such
as PD-L1, CD80/86, TLR, TGF-β, CCL4, and CCL5 (80) (Figure 1,
properties 1 and 4). Additional leucocytic proteins (CXCR4,CCR7,
CCR8) facilitate invasion and proliferation within lymph nodes
(Figure 1, property 2) (35, 42, 81). Processes critical to survival in
circulation, homing to tissue specific sites, and successful extrava-
sation are mediated by E/P-selectins, L-selectin ligands, α4β1,
ICAM-1, and VCAM-1 (61, 73, 82–86) (Figure 1, property 3).
By harnessing mechanisms usually reserved for immune cells,
tumor cells gain the ability to become more aggressive. In the
case of TLRs, a cycle of overexpression and resulting inflamma-
tion promotes plasticity of the epithelial phenotype. This plasticity
permits tumor cells to undergo ELT, accessing immune programs
that facilitate invasion and metastasis of the cancer. ELT, as with
other plastic states, is likely transient, making the evaluation of
these phenotypes a significant challenge. TLR-mediated evolution
of CRC may be a good model to study how ELT occurs, since TLRs
are primarily seen in immune cells and the overexpression of TLRs
appears to promote an immune-like phenotype in CRC.
Understanding the acquisition of the leucocytic phenotype
could reveal key targets that would prevent CRC cells from access-
ing dangerous invasion and trafficking mechanisms through a
plastic transition. Simply antagonizing TLRs and associated mol-
ecules may not be enough, since resistance is likely to develop.
However, if the mechanisms of plasticity induced by TLRs are
understood, new targets may be developed to inhibit ELT.
It is important to note that the key functional activities of
immune cells, specifically the CD8 cytotoxic T-cell phenotype
and the antibody producing activated B-cell phenotypes, have
not yet been described in tumor cells. However, other cytotoxic
mechanisms utilized by immune cells have been seen in normal
and neoplastic epithelial cells. Tumor cell cannibalism, resembling
phagocytosis, of neighboring apoptotic cells as well as infiltrat-
ing immune cells has been seen during times of metabolic stress
(87). During mammary involution, epithelial-derived FAS plays
a role in FASL-mediated cell death (88). Tumor cells can secrete
FAS, TNFa, and TGFb, proteins capable of promoting and inhibit-
ing epithelial cell death (89–91). Additionally, PD-L1 proteins on
tumor cells result in T-cell anergy and apoptosis (92,93). Although,
none of these represent the antigen-specific killing of the adap-
tive immune system, it is our opinion that further exploration is
needed to determine how far epithelial cells can evolve to obtain
immune-like processes and that cell killing can not yet be included
or excluded from that hypothesis.
CONCLUSION
Originally, lymphatic dissemination into draining lymph nodes
was considered a clear indicator of prognosis and was attributed
to tumor chronology based on the correlation of tumor volumes
and lymph node metastasis. However, later larger studies often
showed conflicting results. Jatoi et al. (94, 95) and others attrib-
uted these differences to the tumor phenotype as opposed to a
simple passage of time. This means that tumor phenotypes can
exist on a continuum from slow growing with late lymph node
metastasis to aggressive early disseminators much more capable of
exiting the lymph node and establishment at distant sites (94, 95).
While lymph node positivity is a useful tool for treatment decisions
understanding the complexities of these aggressive phenotypes is
key to halting the lymphatic dissemination of cancer.
Many host parameters contribute to natural progression of
tumor metastasis and the extent of tumor cell plasticity is not
yet fully appreciated. In an opinion article on tumor and immune
cell plasticity, Holzel et al. (68) recognize the similarity between
cancer cells and immune cells by linking inflammation and evolu-
tionary pressures to the creation of plastic phenotypes. We think
that this idea needs to be taken further to include a plastic transi-
tion to an immune-like phenotype, i.e., ELT, in the context tumor
development, invasion, metastasis, and resistance to therapies.
Specifically in CRC, the tumor cells acquire many hallmarks of
the immune system, and this transition is intimately tied to aber-
rant TLR expression. By considering TLR expression in the context
of ELT, the transition to a migratory immune-like and therefore
metastatic phenotype might be better understood, and therefore,
lead to better therapeutic strategies.
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